Center for the Biomedical Advanced Research and Development Authority (BARDA)

Administration for Strategic Preparedness & Response (ASPR)

U.S. Department of Health and Human Services (HHS)

Request for Information (RFI) for

"Repurposing Equipment for Drug Delivery (REDD)"

Issued: June 29, 2026

Responses Due: July 23, 2026, by 1pm ET

Center for the Biomedical Advanced Research and Development Authority (BARDA)

Contracts Management & Acquisition (CMA)

400 7th Street, SW, Washington, DC 20024

MedicalCountermeasures.gov

1. Purpose

The Biomedical Advanced Research and Development Authority (BARDA), Chemical, Biological, Radiological, and Nuclear (CBRN) Division is conducting targeted market research to inform a potential future initiative. This is focused on understanding the research and development landscape and potential offeror abilities to take possession of specialized collapsable primary drug cartridge (PDC) development equipment and repurpose it for a novel drug delivery device (i.e. autoinjector or another single use delivery system). Technologies applicable to chemical medical countermeasures are of primary interest, with preference for platforms that may be broadly applicable across multiple CBRN indications. Commercial applications may exist for this device technology.

2. Scope of Interest

The BARDA CBRN Division, Chemical MCM Program seeks input from industry, academia, and other stakeholders regarding transformative approaches that will repurpose specialized equipment that was originally customized to manufacture an emergency autoinjector platform, featuring a novel glass-free, collapsible, primary drug container (PDC), made from high barrier films. This equipment includes specific items that involve handling, cleaning, forming the Polyvinyl chloride (PVC) film in specific conformations, placement into a pre-assembly configuration, fill, and finishing the sealing of the primary drug cartridge. Details are included in the GFE .pdf document. Specific Information about the equipment and the PDC will be supplied at time of award.

Potential areas of interest include (but are not limited to):

- Novel autoinjector platforms
- Needless drug delivery device

3. Request for Information

The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in understanding the existing capabilities to assume ownership of available equipment and leverage those assets to manufacture an emergency autoinjector platform, featuring a novel glass-free, collapsible, primary drug container (PDC) with the final intent to develop a new drug delivery device or platform.

Respondents do not have to be a member of the Rapid Response Partnership Vehicle (RRPV) consortium to submit a response for this RFI; however, they must be a member

of the consortium to respond to any future Request for Project Proposals (RPP) for this requirement.

Please submit via the RFI Submission Form here by

1pm ET July 23, 2026

Late responses may not be considered

This RFI is for information gathering purposes only. It does not constitute a Request for Project Proposal (RPP), nor does it imply any obligation to issue a future solicitation, make any award, or pay any costs associated with responding to this RFI. Submission is voluntary and does not commit the responder to propose to any subsequent opportunities (if any) related to this topic. The RRPV Consortium will not return or provide feedback on any submissions to this RFI, however, BARDA reserves the right to further engage with respondents in a Market Research Call to clarify understanding of submitted information, as applicable. All responses to this RFI will be treated as sensitive information and confidentiality will be protected accordingly.

4. Requested Information

Respondents are invited to provide a concise response addressing the following topics:

1. Organizational Overview
    a. Brief description of your organization/team, core expertise, and primary focus areas
    b. Summary of prior experience with drug delivery devices (e.g. autoinjectors) and manufacturing
2. Proposed Solution Technical Overview
    a. Discussion of proposed device and address how it differs from current products on the market.
    b. Clear description of your proposed technical solution and address the maturity of your solution: https://medicalcountermeasures.gov/trl; provide data if possible. Where development is needed, provide high-level descriptions of time and work needed.
    c. Provide clear descriptions of platform/workflow/process, including input/output.
    d. Discuss limitations, both fundamental and those with proposed workarounds (e.g., internal development, partnering).
    e. Assessment of existing IP landscape.
3. Infrastructure & Capabilities

    a. Brief description of existing facilities, infrastructure, and capabilities
        i. Identify capability gaps or areas where partners may be needed to integrate your technology/platform into an end-to-end solution.
        ii. For responses that include manufacturing, include information on production scale, readiness, location, and quality (e.g. R&D, pilot, or GMP).
4. Experience & Collaboration
    a. List of relevant collaborations, awards (e.g., BARDA, NIH, DARPA, DoD, industry partnerships) and/or published manuscripts.
    b. Willingness to partner with others for any step in the process
5. Propose Program Structures, Milestones, and Tests
    a. Respondents are encouraged to include high-level concepts for structured development programs (<1 page)
        i. Suggested high-level milestones, metrics, and key decision points for development work and planned pressure tests.
        ii. Estimated timelines and resource needs for such a demonstration

5. Submission Requirements

Interested parties should respond to this RFI with a written response consisting of a cover page and a technical response (PDF; no smaller than 10-point font). The cover page should provide administrative and contact Information (contact name, title, email address, phone number) and organizational information of the responder (entity name, headquarters, mailing address). The technical response should be no longer than 8 pages for end-to-end solutions or 6 pages for individual platforms (excluding the cover page) and include the following:

1. Executive Summary (≤1 page)
2. Technical Overview (≤5 pages for end-to-end solutions; ≤3 pages for individual technologies)
3. Capabilities and Infrastructure (≤1 page)
4. (Optional) Proposed Program or Demonstration Concept (≤1 page, **does** count against page count)

Add references as necessary but be sure to include all relevant information in the response. Cited publications or attachments may not be read.

Respondents must clearly mark all copyrighted information, data, and materials with appropriate restrictive legends (e.g., confidential, privileged, proprietary, trade secret). To aid in protecting your information, please segregate proprietary information. DO NOT SUBMIT ANY CLASSIFIED INFORMATION.

Please note that non-federal employees performing advisory and assistance services will have access to any submission under this RFI. All non-federal employees are required to sign a Non-disclosure Agreement (NDA) prior to accessing the RFI responses.